Home/Filings/4/0001209191-16-124908
4//SEC Filing

Orexigen Therapeutics, Inc. 4

Accession 0001209191-16-124908

CIK 0001382911operating

Filed

Jun 1, 8:00 PM ET

Accepted

Jun 2, 11:22 AM ET

Size

8.0 KB

Accession

0001209191-16-124908

Insider Transaction Report

Form 4
Period: 2016-05-31
Cannell Thomas R
Chief Commercial Officer
Transactions
  • Award

    Common Stock

    2016-05-31$0.34/sh+9,632$3,27514,723 total
Footnotes (1)
  • [F1]Shares acquired under Issuer's 2013 Employee Stock Purchase Plan.

Issuer

Orexigen Therapeutics, Inc.

CIK 0001382911

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001382911

Filing Metadata

Form type
4
Filed
Jun 1, 8:00 PM ET
Accepted
Jun 2, 11:22 AM ET
Size
8.0 KB